arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Intellia Therapeutics, Inc.

NTLA Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances
$12.88
▲ +1.1% Today
as of Sep 4, 16:52 ET
Last 30 days +16.99% Jul 28 → Sep 04
$10.45 $11.27 $12.10 $12.92 $13.74 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$12.59
High
$12.96
Low
$12.52
Volume
$3M
Avg Vol
$6M
Mkt Cap
$1.7B
P/E (TTM)
—
Beta
—
52w High
$28.25
52w Low
$7.95
Div Yield
—
Shares Out
$140M

Recent Press Releases & News last 60 days · 21 items

Sep 5 · 16:13 Simply Wall St.
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
Sep 5 · 09:08 Simply Wall St.
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
Sep 4 · 20:05 PR GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 21 press releases & news Free account →

Overview

52-week range
$7.95
$28
24% of range
Avg surprise (last 3)
+9.5%
Avg reaction (last 2)
+8.0%
100% positive
Latest IV / EM
71%
EM ±11.1% · $13 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.52$-1.34$-1.16$-0.98$-0.80 Actual $-1.17Actual $-1.40Actual $-1.38Actual $-1.12Actual $-1.52Actual $-1.34Actual $-1.10Est $-1.26Actual $-0.99Est $-1.03Actual $-0.92Actual $-0.81Est $-0.92Actual $-0.80 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-136M$-97M$-59M$-21M$17M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.80 — — — — financials
Mon May 11, 2026Mar/2026 $-0.81 $-0.92 +12.0% +26.4% +2.3% earnings
Tue Sep 30, 2025Sep 2025 $-0.92 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.99 $-1.03 +3.9% — — earnings
Thu May 8, 2025Mar/2025 $-1.10 $-1.26 +12.7% — +13.6% earnings
Mon Sep 30, 2024Sep 2024 $-1.34 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.52 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.12 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.38 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.40 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.17 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$8M$15M—$14M$14M$17M—$9M
Cost of revenue————————
Gross profit————————
Operating income$-113M$-101M—$-111M$-110M$-121M—$-145M
Net income$-107M$-96M—$-101M$-101M$-114M—$-136M
EPS (diluted)$-0.80$-0.81—$-0.92$-0.98$-1.10—$-1.34

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$106M$135M$155M$193M$156M$127M$189M$120M
Inventory————————
Total current assets$528M$466M$528M$582M$496M$551M$640M$711M
Total assets$857M$759M$842M$925M$899M$986M$1.19B$1.17B
Long-term debt————————
Total liabilities$129M$138M$171M$177M$184M$206M$319M$211M
Total equity$728M$621M$671M$748M$-715M$780M$872M$963M

Implied volatility — last 90 days

68%102%137%171%206% Jun 07 — IV 127% · EM ±17.5%Jun 08 — IV 115% · EM ±15.2%Jun 09 — IV 101% · EM ±12.7%Jun 10 — IV 110% · EM ±13.0%Jun 11 — IV 105% · EM ±11.7%Jun 12 — IV 116% · EM ±11.9%Jun 15 — IV 132% · EM ±9.5%Jun 16 — IV 135% · EM ±8.0%Jun 17 — IV 206% · EM ±8.6%Jun 19 — IV 97% · EM ±21.5%Jun 22 — IV 96% · EM ±20.0%Jun 23 — IV 89% · EM ±18.2%Jun 24 — IV 86% · EM ±17.2%Jun 25 — IV 90% · EM ±17.6%Jun 26 — IV 100% · EM ±19.1%Jun 29 — IV 95% · EM ±16.9%Jun 30 — IV 96% · EM ±16.6%Jul 01 — IV 115% · EM ±19.1%Jul 02 — IV 91% · EM ±14.7%Jul 03 — IV 96% · EM ±14.9%Jul 06 — IV 84% · EM ±11.6%Jul 07 — IV 88% · EM ±11.7%Jul 08 — IV 92% · EM ±11.6%Jul 09 — IV 102% · EM ±12.1%Jul 10 — IV 95% · EM ±10.5%Jul 13 — IV 106% · EM ±8.8%Jul 14 — IV 135% · EM ±9.8%Jul 15 — IV 123% · EM ±7.3%Jul 16 — IV 95% · EM ±4.0%Jul 20 — IV 95% · EM ±22.5%Jul 21 — IV 107% · EM ±24.9%Jul 22 — IV 75% · EM ±17.1%Jul 23 — IV 76% · EM ±17.1%Jul 24 — IV 93% · EM ±20.5%Jul 27 — IV 73% · EM ±15.2%Jul 28 — IV 98% · EM ±20.0%Jul 29 — IV 86% · EM ±17.3%Jul 30 — IV 83% · EM ±16.2%Jul 31 — IV 92% · EM ±17.6%Aug 03 — IV 86% · EM ±15.3%Aug 04 — IV 88% · EM ±15.2%Aug 05 — IV 86% · EM ±14.4%Aug 06 — IV 91% · EM ±14.8%Aug 07 — IV 84% · EM ±13.1%Aug 10 — IV 75% · EM ±10.4%Aug 11 — IV 79% · EM ±10.4%Aug 12 — IV 72% · EM ±9.1%Aug 13 — IV 71% · EM ±8.3%Aug 14 — IV 68% · EM ±7.5%Aug 17 — IV 76% · EM ±6.4%Aug 18 — IV 90% · EM ±6.5%Aug 19 — IV 89% · EM ±5.3%Aug 20 — IV 105% · EM ±4.4%Aug 24 — IV 71% · EM ±14.9%Aug 25 — IV 102% · EM ±20.8%Aug 26 — IV 83% · EM ±16.7%Aug 27 — IV 97% · EM ±18.9%Aug 28 — IV 83% · EM ±15.9%Aug 31 — IV 80% · EM ±14.1%Sep 01 — IV 88% · EM ±15.1%Sep 02 — IV 89% · EM ±14.9%Sep 03 — IV 80% · EM ±13.0%Sep 04 — IV 71% · EM ±11.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in